Bölüm notları
In this video podcast, Prof. Giuseppe Curigliano and Dr Javier Cortés explore how TROP2-directed antibody–drug conjugates (ADCs) are shaping 1st line treatment for metastatic triple-negative breast cancer (TNBC).
Key clinical takeaways:
Earlier placement: TROPION-Breast02 and ASCENT-03 support 1st line TROP2 ADC use in defined patients who are not candidates for an ICI; ASCENT-04 supports SG plus pembrolizumab in the studied PD-L1-positive population
Individualised selection: Apply each trial to the appropriate patient. Consider disease characteristics, prior therapy, schedule and AE…
Web sitesi: oncology-medical-conversation-video.castos.com

